Profile of omalizumab in the treatment of chronic spontaneous urticaria

Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE...

Full description

Bibliographic Details
Authors: Labrador Horrillo, Moises|||0000-0003-3222-2380, Ferrer, Marta|||0000-0001-8495-1302
Format: article
Publication Date:2015
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:185412
Online Access:https://ddd.uab.cat/record/185412
https://dx.doi.org/urn:doi:10.2147/DDDT.S56004
Access Level:Open access
Keyword:Omalizumab
Chronic spontaneous urticaria
Antihistamines
Subcutaneous administration
Add-on therapy
id ES_d54cf77eb2edf7d75a712e68bfc08887
oai_identifier_str oai:ddd.uab.cat:185412
network_acronym_str ES
network_name_str España
repository_id_str
spelling Profile of omalizumab in the treatment of chronic spontaneous urticariaLabrador Horrillo, Moises|||0000-0003-3222-2380Ferrer, Marta|||0000-0001-8495-1302OmalizumabChronic spontaneous urticariaAntihistaminesSubcutaneous administrationAdd-on therapyChronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. It has been largely studied in the field of asthma and is currently approved for the treatment of both adult and pediatric (children; >6-year-old) patients. In addition, in recent, well-controlled clinical trials in patients with CSU resistant to antihistamines, add-on therapy with subcutaneous omalizumab significantly reduced the severity of itching, and the number and size of hives, and increased patients' health-related QoL and the proportion of days free from angioedema compared with placebo, with an excellent tolerance. Thus, omalizumab is an effective and well-tolerated add-on therapy for patients with CSU who are symptomatic despite background therapy with H1 antihistamines. In this review, we cover the following points: epidemiology, pathogenesis, assessment of activity, impact on QoL, and treatment of CSU, and finally, we focus on omalizumab in the treatment of CSU including the pharmacokinetic properties and mechanism of action, and use in pregnant women, nursing infants, and children.Universitat Autònoma de Barcelona. Departament de Medicina 22015-01-0120152015-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/185412https://dx.doi.org/urn:doi:10.2147/DDDT.S56004reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:1854122026-06-06T12:50:31Z
dc.title.none.fl_str_mv Profile of omalizumab in the treatment of chronic spontaneous urticaria
title Profile of omalizumab in the treatment of chronic spontaneous urticaria
spellingShingle Profile of omalizumab in the treatment of chronic spontaneous urticaria
Labrador Horrillo, Moises|||0000-0003-3222-2380
Omalizumab
Chronic spontaneous urticaria
Antihistamines
Subcutaneous administration
Add-on therapy
title_short Profile of omalizumab in the treatment of chronic spontaneous urticaria
title_full Profile of omalizumab in the treatment of chronic spontaneous urticaria
title_fullStr Profile of omalizumab in the treatment of chronic spontaneous urticaria
title_full_unstemmed Profile of omalizumab in the treatment of chronic spontaneous urticaria
title_sort Profile of omalizumab in the treatment of chronic spontaneous urticaria
dc.creator.none.fl_str_mv Labrador Horrillo, Moises|||0000-0003-3222-2380
Ferrer, Marta|||0000-0001-8495-1302
author Labrador Horrillo, Moises|||0000-0003-3222-2380
author_facet Labrador Horrillo, Moises|||0000-0003-3222-2380
Ferrer, Marta|||0000-0001-8495-1302
author_role author
author2 Ferrer, Marta|||0000-0001-8495-1302
author2_role author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona. Departament de Medicina
dc.subject.none.fl_str_mv Omalizumab
Chronic spontaneous urticaria
Antihistamines
Subcutaneous administration
Add-on therapy
topic Omalizumab
Chronic spontaneous urticaria
Antihistamines
Subcutaneous administration
Add-on therapy
description Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. It has been largely studied in the field of asthma and is currently approved for the treatment of both adult and pediatric (children; >6-year-old) patients. In addition, in recent, well-controlled clinical trials in patients with CSU resistant to antihistamines, add-on therapy with subcutaneous omalizumab significantly reduced the severity of itching, and the number and size of hives, and increased patients' health-related QoL and the proportion of days free from angioedema compared with placebo, with an excellent tolerance. Thus, omalizumab is an effective and well-tolerated add-on therapy for patients with CSU who are symptomatic despite background therapy with H1 antihistamines. In this review, we cover the following points: epidemiology, pathogenesis, assessment of activity, impact on QoL, and treatment of CSU, and finally, we focus on omalizumab in the treatment of CSU including the pharmacokinetic properties and mechanism of action, and use in pregnant women, nursing infants, and children.
publishDate 2015
dc.date.none.fl_str_mv 2
2015-01-01
2015
2015-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/185412
https://dx.doi.org/urn:doi:10.2147/DDDT.S56004
url https://ddd.uab.cat/record/185412
https://dx.doi.org/urn:doi:10.2147/DDDT.S56004
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420667900788736
score 15,812429

Similar Items